Arch Biopartners Inc.
ACHFF · OTC
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | -$0 |
| % Growth | – | -100% | 132.6% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | -$0 | $0 | -$1 |
| % Margin | 27.4% | – | 13.3% | 207.8% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$0 | $0 | $0 | -$0 |
| Operating Expenses | $0 | $1 | $0 | $0 |
| Operating Income | -$0 | -$1 | -$0 | -$1 |
| % Margin | -174.2% | – | -302.9% | 318% |
| Other Income/Exp. Net | $0 | -$0 | -$0 | $0 |
| Pre-Tax Income | -$0 | -$1 | -$0 | -$1 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$0 | -$1 | -$0 | -$1 |
| % Margin | -153.3% | – | -352.9% | 305.8% |
| EPS | -0.004 | -0.01 | -0.006 | -0.018 |
| % Growth | 61.5% | -50% | 64.8% | – |
| EPS Diluted | -0.004 | -0.01 | -0.006 | -0.018 |
| Weighted Avg Shares Out | 66 | 65 | 65 | 61 |
| Weighted Avg Shares Out Dil | 66 | 65 | 65 | 61 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $1 | $0 | $1 |
| EBITDA | -$0 | -$0 | -$0 | $0 |
| % Margin | -116.1% | – | -78.6% | -0% |